Skip to ContentSkip to Navigation
About us Latest news News News articles

Development and evaluation of PET tracers for imaging B-glucuronidase activity in cancer and inflammation

25 January 2012

Ph ceremony: Ms. I. Farinha Antunes, 14.30 uur, Aula Academiegebouw, Broerstraat 5, Groningen

Disseration: Development and evaluation of PET tracers for imaging B-glucuronidase activity in cancer and inflammation

Promotor(s): prof. R.A.J.O.Dierckx, prof. H.G. Haisma, prof. P.H. Elsinga

Faculty: Medical Sciences

The ideal treatment should cure a disease without harming healthy tissues. Therefore, a new treatment strategy for cancer and certain inflammatory diseases has been developed called Prodrug therapy. In this approach, a toxic drug is “disguised” as a non-toxic compound called prodrug, which can be reactivated by an enzyme at the target site, releasing the drug only where it is needed. β-Glucuronidase is being explored as an enzyme to activate prodrugs. Not every patient possesses the same amount of β-glucuronidase at the target site. PET imaging of β-glucuronidase activity could allow monitoring β-glucuronidase activity over time. Provided that a suitable tracer is available, PET might give information about the levels of β-glucuronidase present in various tissues in a patient. Thus, PET might be used to predict which patients would benefit from β-glucuronidase prodrug therapy.

The aim of this project was to develop a PET tracer for imaging β-glucuronidase activity and to use it for evaluation of β-glucuronidase in animal models for various disorders. Our in vivo studies show that the PET tracer [18F]FEAnGA can detect and quantify extracellular β-glucuronidase activity in tumors, in sterile inflammatory lesions and in brain infection. We were also able to demonstrate with [18F]FEAnGA PET that a single dose of cytostatic drug can increase β-glucuronidase activity in tumors. This study may open the way to a two-step chemotherapy-prodrug approach, in which tumors are treated with a single dose of a cytostatic drug to increase the levels of β-glucuronidase prior the prodrug treatment.

Last modified:13 March 2020 12.59 a.m.
Share this Facebook LinkedIn
View this page in: Nederlands

More news

  • 06 June 2025

    India-Netherlands Hydrogen Valley Fellowship Programme announced

    To coincide with World Environment Day, 5 June 2025, the Indian Department of Science and Technology and the University of Groningen yesterday announced a Hydrogen Valley Fellowship Programme Partnership, allowing talented Indian scholars working on...

  • 28 May 2025

    Gaan avondmensen cognitief sneller achteruit dan ochtendmensen?

    Wie ’s avonds opleeft en laat naar bed gaat, heeft een grotere kans op cognitieve achteruitgang dan een ochtendmens, blijkt uit UMCG-onderzoek.

  • 27 May 2025

    An adventure in the brain

    In the exhibition Brainstorm in the University Mueseum, Iris Sommer and two other brain researchers from Groningen explain the gut-brain connection, how it was discovered that the brain does what it does, and how games motivate you to perform...